Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

Cosmos Health Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHICAGO, AUG. 12, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. (COSMOS HEALTH OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP, ANNOUNCED TODAY THAT IT HAS COMMENCED PURCHASES OF ETHEREUM (ETH), ADVANCING ITS DIGITAL ASSET TREASURY RESERVE STRATEGY. PURSUANT TO ITS FINANCING FACILITY OF UP TO $300 MILLION (THE FACILITY) WITH A U.S.-BASED INSTITUTIONAL INVESTOR, COSMOS HEALTH HAS COMPLETED ITS INITIAL $1 MILLION PURCHASE OF ETH.

COSMOS HEALTH MAKES INITIAL $1M ETHEREUM PURCHASE UNDER DIGITAL ASSET TREASURY STRATEGY

COSMOS HEALTH SECURES FINANCING OF UP TO $300 MILLION TO DEVELOP AN ETH-BACKED TREASURY, WITH REMAINING PROCEEDS FOR GROWTH AND GENERAL WORKING CAPITAL

COSMOS HEALTH SECURES UP TO $300 MILLION FINANCING FACILITY TO LAUNCH ETHEREUM TREASURY STRATEGY

CHICAGO, JUNE 24, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY'') (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP ENGAGED IN INNOVATIVE R&D, OWNER OF PROPRIETARY PHARMACEUTICAL AND NUTRACEUTICAL BRANDS, MANUFACTURER AND DISTRIBUTOR OF HEALTHCARE PRODUCTS, AND OPERATOR OF A TELEHEALTH PLATFORM, ANNOUNCED TODAY ITS ENTRY INTO THE U.S. MARKET AND THE LAUNCH OF U.S.-BASED MANUFACTURING THROUGH A STRATEGIC AGREEMENT WITH DOLCAS BIOTECH LLC (DOLCAS), A NEW JERSEY-BASED DEVELOPER AND MANUFACTURER OF CLINICALLY STUDIED NUTRACEUTICAL INGREDIENTS. COSMOS HEALTH IS SET TO COMMENCE PRODUCTION IN THE UNITED STATES AT GMP-CERTIFIED (GOOD MANUFACTURING PRACTICE) FACILITIES, MARKING A SIGNIFICANT MILESTONE IN THE COMPANY'S OPERATIONAL EXPANSION.

COSMOS HEALTH ENTERS U.S. MARKET WITH STRATEGIC MADE-IN-AMERICA MANUFACTURING, MITIGATING TARIFF RISKS; EXECUTES AGREEMENT WITH NEW JERSEY-BASED DOLCAS BIOTECH

CHICAGO, MAY 15, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY) (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP ENGAGED IN INNOVATIVE R&D, OWNER OF PROPRIETARY PHARMACEUTICAL AND NUTRACEUTICAL BRANDS, MANUFACTURER AND DISTRIBUTOR OF HEALTHCARE PRODUCTS, AND OPERATOR OF A TELEHEALTH PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. FIRST QUARTER 2025 FINANCIAL HIGHLIGHTS INCOME STATEMENT COSMOS HEALTH DELIVERED SOLID RESULTS IN Q1 2025, HIGHLIGHTED BY A SIGNIFICANT INCREASE IN GROSS PROFIT AND POSITIVE PERFORMANCE ON BOTH AN ADJUSTED EBITDA AND ADJUSTED NET INCOME BASIS, REFLECTING A MEANINGFUL TURNAROUND IN BOTTOM-LINE PERFORMANCE.

RETRANSMISSION  COSMOS HEALTH REPORTS Q1 2025 RESULTS: ADJUSTED PROFITABILITY ACHIEVED AS GROSS PROFIT RISES 54% TO $2.05M; OPERATING CASH BURN DOWN 95%, OR $3.2M, TO $0.19M; APPROACHING CASH FLOW BREAKEVEN

COSMOS HEALTH REPORTS Q1 2025 RESULTS: ADJUSTED PROFITABILITY ACHIEVED AS GROSS PROFIT RISES 54% TO $2.05M; OPERATING CASH BURN DOWN 95%, OR $3.2M, TO $0.19M; APPROACHING CASH FLOW BREAKEVEN

CHICAGO, MAY 07, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY'') (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP ENGAGED IN INNOVATIVE R&D, OWNER OF PROPRIETARY PHARMACEUTICAL AND NUTRACEUTICAL BRANDS, MANUFACTURER AND DISTRIBUTOR OF HEALTHCARE PRODUCTS, AND OPERATOR OF A TELEHEALTH PLATFORM, ANNOUNCED TODAY THAT IT HAS RECEIVED AN ADDITIONAL PURCHASE ORDER FOR 80,000 UNITS FROM PHARMALINK FOR ITS SKY PREMIUM LIFE PRODUCTS IN THE UNITED ARAB EMIRATES (UAE). THIS LATEST ORDER, PURSUANT TO THE EXCLUSIVE DISTRIBUTION AGREEMENT WITH PHARMALINK, FOLLOWS THE SUCCESSFUL SELL-OUT OF THE INITIAL 130,000-UNIT PURCHASE AND SUPPORTS THE COMPANY'S OBJECTIVE OF SURPASSING 3 MILLION UNITS IN CUMULATIVE ORDERS OVER THE FIRST FIVE YEARS.

COSMOS HEALTH SECURES FOLLOW-UP ORDER FROM PHARMALINK FOR 80,000 SKY PREMIUM LIFE UNITS IN THE UAE; INITIAL 130,000-UNIT ORDER SOLD OUT, ADVANCING 5-YEAR GOAL OF OVER 3 MILLION UNITS

WATERTOWN, MASS., MAY 07, 2025 (GLOBE NEWSWIRE) -- LYRA THERAPEUTICS, INC.(NASDAQ: LYRA), (LYRA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING LONG-ACTING, ANTI-INFLAMMATORY SINONASAL IMPLANTS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS (CRS),TODAY ANNOUNCED THAT THE COMPANY PLANS TO PRESENT RESULTS FROM THE 52-WEEK EXTENSION STAGE OF THE ENLIGHTEN 1 PHASE 3 STUDY FOR LYR-210, THE COMPANY'S LEAD PRODUCT CANDIDATE FOR CRS, AT THE ANNUAL COMBINED OTOLARYNGOLOGY SPRING MEETINGS (COSM 2025) BEING HELD MAY 14-18 IN NEW ORLEANS.

LYRA THERAPEUTICS TO PRESENT 52-WEEK EXTENSION STAGE RESULTS FOR ENLIGHTEN 1 PHASE 3 STUDY FOR LYR-210 FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS AT COSM 2025

CHICAGO, MAY 06, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY'') (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP ENGAGED IN INNOVATIVE R&D, OWNER OF PROPRIETARY PHARMACEUTICAL AND NUTRACEUTICAL BRANDS, MANUFACTURER AND DISTRIBUTOR OF HEALTHCARE PRODUCTS, AND OPERATOR OF A TELEHEALTH PLATFORM, ANNOUNCED TODAY THAT IT HAS RECEIVED FORMAL NOTICE FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) INDICATING THAT THE COMPANY IS ELIGIBLE FOR AN ADDITIONAL 180 CALENDAR DAY PERIOD, THROUGH NOVEMBER 3, 2025, TO REGAIN COMPLIANCE WITH THE NASDAQ'S MINIMUM BID PRICE REQUIREMENT. AS PREVIOUSLY DISCLOSED, ON NOVEMBER 6, 2024, THE COMPANY WAS NOTIFIED BY NASDAQ THAT IT WAS NOT IN COMPLIANCE WITH THE $1.00 MINIMUM BID PRICE REQUIREMENT, AS THE CLOSING BID PRICE OF THE COMPANY'S COMMON STOCK HAD REMAINED BELOW $1.00 FOR 30 CONSECUTIVE BUSINESS DAYS.

COSMOS HEALTH RECEIVES ADDITIONAL 180-DAY COMPLIANCE PERIOD FROM NASDAQ

NEW YORK , MAY 5, 2025 /PRNEWSWIRE/ -- BAIRD MEDICAL INVESTMENT HOLDINGS LTD. (NASDAQ: BDMD) ("BAIRD MEDICAL" OR THE "COMPANY"), A GLOBAL LEADER IN MINIMALLY INVASIVE MICROWAVE ABLATION (MWA) TECHNOLOGY, IS PLEASED TO ANNOUNCE ITS PARTICIPATION IN THE 2025 COMBINED OTOLARYNGOLOGY SPRING MEETINGS (COSM), TAKING PLACE MAY 14-18, 2025, IN NEW ORLEANS, LOUISIANA.

BAIRD MEDICAL TO PARTICIPATE IN COSM 2025 CONFERENCE

CHICAGO, APRIL 30, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY'') (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP ENGAGED IN INNOVATIVE R&D, OWNER OF PROPRIETARY PHARMACEUTICAL AND NUTRACEUTICAL BRANDS, MANUFACTURER AND DISTRIBUTOR OF HEALTHCARE PRODUCTS, AND OPERATOR OF A TELEHEALTH PLATFORM, ANNOUNCED TODAY THAT ITS CEO, GREG SIOKAS, HAS INCREASED HIS STAKE IN THE COMPANY BY ACQUIRING A TOTAL OF 1,466,764 COMMON SHARES, VALUED AT $526,000, ACROSS FIVE TRANSACTIONS BETWEEN APRIL 21, 2025, AND APRIL 24, 2025. AS A RESULT OF THESE TRANSACTIONS, MR.

COSMOS HEALTH CEO GREG SIOKAS ACQUIRES 1,466,764 SHARES VALUED AT $526,000 OVER THE PAST WEEK; 2,777,469 SHARES ACQUIRED OVER THE PAST FIVE MONTHS FOR $1,325,000

CHICAGO, APRIL 16, 2025 (GLOBE NEWSWIRE) -- COSMOS HEALTH INC. ("COSMOS HEALTH" OR THE COMPANY'') (NASDAQ:COSM) , A DIVERSIFIED, VERTICALLY INTEGRATED GLOBAL HEALTHCARE GROUP ENGAGED IN INNOVATIVE R&D, OWNER OF PROPRIETARY PHARMACEUTICAL AND NUTRACEUTICAL BRANDS, MANUFACTURER AND DISTRIBUTOR OF HEALTHCARE PRODUCTS, AND OPERATOR OF A TELEHEALTH PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2024. FULL YEAR 2024 FINANCIAL HIGHLIGHTS INCOME STATEMENT: FY 2024 PERFORMANCE WAS MARKED BY REVENUE GROWTH, AN INCREASE IN R&D INVESTMENTS, AND A SUBSTANTIAL REDUCTION IN OPERATING EXPENSES, WHILE BOTTOM-LINE RESULTS WERE IMPACTED BY THE ABSENCE OF NON-RECURRING GAINS RECOGNIZED IN THE PRIOR YEAR.

Cosmos Health Inc.

COSM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cosmos Health Inc.

COSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

COSM